2026-01-27 - Analysis Report
**Philip Morris International Inc. Review**
=====================================

### Company Overview
Philip Morris International Inc. (PM) is a multinational tobacco company that sells and markets a variety of tobacco products worldwide.

### Cumulative Return Comparison
| Ticker | Cumulative Return |
|--------|-------------------|
| PM     | 138.59%           |
| VOO    | 127.58%           |

The cumulative return of PM is higher than that of the S&P 500 (VOO) by 11.01%.

### Alpha, Beta Analysis
| Year    | CAGR | MDD  | Alpha | Beta | Cap(B) |
|---------|------|------|-------|------|-------|
| 2016-2018 | -26.0% | 22.9% | -35.0% | 0.5  | 103.9B |
| 2017-2019 | -1.0%  | 22.9% | -27.0% | 0.5  | 132.4B |
| 2018-2020 | -3.0%  | 31.0% | -27.0% | 0.8  | 128.9B |
| 2019-2021 | 40.0%  | 31.0% | -24.0% | 0.8  | 147.9B |
| 2020-2022 | 36.0%  | 31.0% | 32.0%  | 0.7  | 157.6B |
| 2021-2023 | 26.0%  | 19.7% | 8.0%   | 0.5  | 146.4B |
| 2022-2024 | 32.0%  | 19.7% | 3.0%   | 0.4  | 187.3B |
| 2023-2025 | 79.0%  | 19.8% | 4.0%   | 0.2  | 249.7B |

### Recent Stock Price Fluctuations
| Metric              | Value     |
|---------------------|-----------|
| Close               | $175.76  |
| Last-Market Change  | $1.58    |
| 5-day SMA           | $170.96  |
| 20-day SMA          | $165.02  |
| 60-day SMA          | $157.37  |

### RSI, PPO Index, and Divergence Analysis
| Indicator    | Value   |
|--------------|---------|
| Market Risk Indicator (MRI) | 0.70    |
| RSI          | 70.81   |
| PPO          | 0.48    |
| Hybrid Signal | Buy     |
| Recent Divergence | improving |
| 7-day Rank Change | -6 (-) |
| 7-day Dynamic Expected Return change | -10.00 (-) |
| Expected Return | -16.50% |

### News and Significant Events
[2026-01-12] Earnings Preview: What to Expect From Philip Morris’ Report - Yahoo Finance
[2026-01-26] Philip Morris International (NYSE:PM) Valuation After FDA Progress On ZYN Modified Risk Review - simplywall.st
[2026-01-26] Savoir Faire Capital Management L.P. Grows Stock Position in Philip Morris International Inc. $PM - MarketBeat
[2026-01-24] Philip Morris International: A Stock Analysis You Can't Miss - The Motley Fool
[2026-01-24] Philip Morris International: A Stock Analysis You Can't Miss - Nasdaq
[2026-01-26] PM: Gov’t keen to secure strategic stock of medicines, medical supplies - الهيئة العامة للاستعلامات

### Analyst Opinions
 Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.83 (~Buy)
- Opinions: 16
- Target Price (avg/high/low): $180.38 / $200.00 / $158.00

### Recent Earnings Analysis
| Date       | EPS | Revenue |
|------------|-----|---------|
| 2025-10-24 | 2.23 | $10.85B |
| 2025-07-25 | 1.95 | $10.14B |
| 2025-04-24 | 1.72 | $9.30B  |
| 2024-10-24 | 1.98 | $9.91B  |
| 2025-10-24 | 1.98 | $9.91B  |

Earnings per share (EPS) and revenue have shown consistent growth over the past year.

### Financial Information
#### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $10.85B | 67.85%        |
| 2025-06-30 | $10.14B | 67.66%        |
| 2025-03-31 | $9.30B  | 67.32%        |
| 2024-12-31 | $9.71B  | 64.73%        |
| 2024-09-30 | $9.91B  | 66.04%        |

#### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | -$10.91B| -31.87% |
| 2025-06-30 | -$11.97B| -25.40% |
| 2025-03-31 | -$10.90B| -24.68% |
| 2024-12-31 | -$11.75B| 4.93%  |
| 2024-09-30 | -$9.69B | -31.79% |

Equity and return on equity (ROE) have shown significant fluctuations over the past year.

### Comprehensive Analysis

Philip Morris International Inc. has shown a higher cumulative return compared to the S&P 500. The company's alpha and beta values have been relatively stable over the past few years. The recent stock price fluctuations indicate a mild upward trend. The RSI, PPO, and hybrid signal indicate a buy signal, while the recent divergence and 7-day rank change suggest a weakening trend. The expected return is negative, indicating a potential risk in investing in the stock. The news and significant events section suggests that the company is focused on its earnings preview and FDA progress. The analyst opinions section indicates a buy consensus with a target price of $180.38. The recent earnings analysis shows consistent growth in EPS and revenue. The financial information section suggests that revenue and profit margin have shown growth, while equity and ROE have fluctuated.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.